Publications by authors named "Griffith Jenny"

Claim this Profile
E
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.
Edward V Loftus, Geert D'Haens, Edouard Louis, Miguel Regueiro, Vipul Jairath, Jenny Griffith

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.
Bruce E Sands, Silvio Danese, J Casey Chapman, Khushboo Gurjar, Stacy Grieve, Jenny Griffith

Inflamm Bowel Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
Remo Panaccione, Christopher Ma, Vipul Jairath, Axel Dignass, Namita Joshi, Jenny Griffith

J Crohns Colitis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease.
Brian G Feagan, Remo Panaccione, Stefan Schreiber, Edward V Loftus, Laurent Peyrin-Biroulet, Jenny Griffith

Gastro Hep Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's Disease.
Brian G Feagan, Jean-Frederic Colombel, Remo Panaccione, Stefan Schreiber, Marc Ferrante, Jenny Griffith

Gastro Hep Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Pathways in Patients With Crohn's Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy.
Corey A Siegel, Dolly Sharma, Jenny Griffith, Quynhchau Doan, Si Xuan

Crohns Colitis 360· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Jean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, Joanne Rizzo, Kristina Kligys, Jenny Griffith

J Crohns Colitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Marla Dubinsky, Christopher Ma, Jenny Griffith, Marjorie Crowell, Ezequiel Neimark

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden of Fatigue in Inflammatory Bowel Disease.
Ashwin N Ananthakrishnan, Raj Desai, Wan-Ju Lee, Jenny Griffith, Naijun Chen

Crohns Colitis 360· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Edward V Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Laurent Peyrin-Biroulet, Subrata Ghosh, Scott D Lee, Wan-Ju Lee, Jenny Griffith

Aliment Pharmacol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis.
Ryan C Ungaro, Jenny Griffith, Viviana Garcia-Horton, Aolin Wang, Raymond K Cross

Crohns Colitis 360· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies.
David T Rubin, Jenny Griffith, Qisu Zhang, Zsolt Hepp, Allison Keshishian

Inflamm Bowel Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
Chapman Casey, Griffith Jenny, Bruno Michelle, Lynch Joe, McClain Jasmaine

Am J Gastroenterol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry.
Leslie R Harrold, Jenny Griffith, Patrick Zueger, Heather J Litman, Bernice Gershenson

J Rheumatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
Rahel Ehrenberg, Jenny Griffith, Cindy Theigs, Bryan McDonald

J Manag Care Spec Pharm· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab.
Michael Chiorean, Anita Afzali, Raymond K Cross, Dendy Macaulay, Jenny Griffith

Crohns Colitis 360· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis.
Christina A Spivey, Kevin L Winthrop, Jenny Griffith, Cameron M Kaplan, Yanru Qiao

Rheumatol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.
Leslie R Harrold, Pankaj A Patel, Jenny Griffith, Heather J Litman, Hua Feng

Clin Rheumatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
Yan Song, Keith A Betts, Yichen Lu, Rakesh Singh, Jerry Clewell, Jenny Griffith

Rheumatol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.
Arthur Kavanaugh, Rakesh Singh, Chitra Karki, Carol J Etzel, Joel M Kremer, Jenny Griffith

Clin Rheumatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States.
Christina A Spivey, Jenny Griffith, Cameron Kaplan, Arnold Postlethwaite, Arijit Ganguli

Rheumatol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.
Vibeke Strand, M Elaine Husni, Keith A Betts, Yan Song, Rakesh Singh, Jenny Griffith

BMC Rheumatol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.
Dimitrios A Pappas, Joel M Kremer, Jenny Griffith, George Reed, Bob Salim

Rheumatol Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
M Elaine Husni, Keith A Betts, Jenny Griffith, Yan Song, Arijit Ganguli

Rheumatol Int· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis